Senzime AB (publ) (SNZZF)
OTCMKTS · Delayed Price · Currency is USD
0.6175
0.00 (0.00%)
Feb 11, 2026, 9:30 AM EST
Senzime AB Revenue
Senzime AB had revenue of 26.48M SEK in the quarter ending September 30, 2025, with 52.12% growth. This brings the company's revenue in the last twelve months to 89.71M, up 62.24% year-over-year. In the year 2024, Senzime AB had annual revenue of 58.48M with 63.55% growth.
Revenue (ttm)
89.71M SEK
Revenue Growth
+62.24%
P/S Ratio
8.50
Revenue / Employee
1.66M SEK
Employees
54
Market Cap
80.95M USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 58.48M | 22.72M | 63.55% |
| Dec 31, 2023 | 35.75M | 21.72M | 154.77% |
| Dec 31, 2022 | 14.03M | 3.05M | 27.81% |
| Dec 31, 2021 | 10.98M | 1.64M | 17.60% |
| Dec 31, 2020 | 9.34M | 2.63M | 39.13% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zomedica | 29.45M |
| OpGen | 9.00M |
| Tian'an Technology Group | 2.12M |
| PetVivo Holdings | 1.41M |
| Positron | 486.45K |
| Guided Therapeutics | 178.00K |
| CS Diagnostics | 98.73K |
| Vivos | 48.62K |
Senzime AB News
- 22 days ago - Senzime Secures Major Ivy League US Hospital System Contract - Accesswire
- 2 months ago - Senzime's Next-Generation TetraGraph System Receives Regulatory Approval in Japan - Accesswire
- 2 months ago - Senzime Unveils the Next Set of Innovations in Neuromuscular Monitoring With the Launch of EMGINE Sirius - Accesswire
- 2 months ago - Senzime Secures Major TetraGraph Order from Leading UK NHS Hospital System - Accesswire
- 3 months ago - Senzime to Present at Redeye and BioStock Investor Conferences - Accesswire
- 3 months ago - Nomination Committee for Senzime Annual General Meeting 2026 - Accesswire
- 3 months ago - Senzime AB (publ) (SNZZF) Q3 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 3 months ago - Senzime Q3 2025: Strong Growth and Clear Steps Towards Profitability - Accesswire